Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cellsA S Chong, P N Markham, H M Gebel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1997
The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanismsR T Elder, X Xu, J W Williams, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 20, 1998
Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 productionK Siemasko, A S Chong, H M Jäck, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1997
In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr miceX Xu, L Blinder, J Shen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 17, 2013
Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4IgJ Chen, H Yin, J Xu, et al.
Transplantation|June 1, 1993
Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferationA S Chong, A Finnegan, X Jiang, et al.
Pageof 8